




<b>ISSUE DATE</b> November 8, 2024	<b>EFFECTIVE DATE</b> January 6, 2025	<b>NUMBER</b> *See below
<b>SUBJECT</b> Prior Authorization of Monoclonal Antibodies (MABs) – Anti-IL, Anti-IgE, Anti-TSLP – Pharmacy Services		<b>BY</b>  Sally Kozak Deputy Secretary Office of Medical Assistance Programs

**IMPORTANT REMINDER:** All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.pa.gov/en/agencies/dhs/resources/for-providers/provider-enrollment-information/provider-enrollment-documents.html>.

**PURPOSE:**

The purpose of this bulletin is to issue updated handbook pages that include the requirements for prior authorization and the type of information needed to evaluate the medical necessity of prescriptions for Monoclonal Antibodies (MABs) – Anti-IL, Anti-IgE, Anti-TSLP submitted for prior authorization.

**SCOPE:**

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program. The guidelines to determine the medical necessity of MABs – Anti-IL, Anti-IgE, Anti-TSLP will be utilized in the fee-for-service and managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should address any questions related to the prior authorization of MABs – Anti-IL, Anti-IgE, Anti-TSLP to the appropriate managed care organization.

**BACKGROUND/DISCUSSION:**

The Department of Human Services (Department) is updating the medical necessity guidelines for MABs – Anti-IL, Anti-IgE, Anti-TSLP to consider therapeutically equivalent interchangeable biosimilars or brand or unbranded biologics when evaluating a request for a non-preferred MABs – Anti-IL, Anti-IgE, Anti-TSLP. There are no other changes to the medical necessity guidelines.

*01-25-08	09-25-08	27-25-08	33-25-08
02-25-08	11-25-08	30-25-08	
03-25-08	14-25-08	31-25-08	
08-25-09	24-25-08	32-25-08	

**COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:**

Fee-for-Service Provider Service Center: 1-800-537-8862

Visit the Office of Medical Assistance Programs website at:

<https://www.pa.gov/en/agencies/dhs/departments-offices/omap-info.html>

The revisions to the guidelines to determine medical necessity of prescriptions for MABs – Anti-IL, Anti-IgE, Anti-TSLP were subject to public review and comment and subsequently approved for implementation by the Department.

**PROCEDURE:**

The procedures for prescribers to request prior authorization of MABs – Anti-IL, Anti-IgE, Anti-TSLP are located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapter related to MABs – Anti-IL, Anti-IgE, Anti-TSLP) when reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code § 1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs and products that require prior authorization.

**ATTACHMENTS:**

Prior Authorization of Pharmaceutical Services Handbook - Updated pages

**RESOURCES:**

Prior Authorization of Pharmaceutical Services Handbook – SECTION I  
Pharmacy Prior Authorization General Requirements

<https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/pharmacy-prior-authorization-general-requirements.html>

Prior Authorization of Pharmaceutical Services Handbook – SECTION II  
Pharmacy Prior Authorization Guidelines

<https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/clinical-guidelines.html>

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

**I. Requirements for Prior Authorization of Monoclonal Antibodies – Anti-IL, Anti-IgE, Anti-TSLP (MABs – Anti-IL, Anti-IgE, Anti-TSLP)**

**A. Prescriptions That Require Prior Authorization**

All prescriptions for MABs – Anti-IL, Anti-IgE, Anti-TSLP must be prior authorized.

**B. Review of Documentation for Medical Necessity**

In evaluating a request for prior authorization of a prescription for a MAB – Anti-IL, Anti-IgE, Anti-TSLP, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. For Dupixent (dupilumab), see the prior authorization guideline related to Dupixent (dupilumab); **OR**
2. Is prescribed the MAB – Anti-IL, Anti-IgE, Anti-TSLP for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication; **AND**
3. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
4. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
5. Is prescribed the MAB – Anti-IL, Anti-IgE, Anti-TSLP by or in consultation with an appropriate specialist (i.e., pulmonologist, allergist, immunologist, dermatologist, hematologist/oncologist, rheumatologist, etc.); **AND**
6. If currently using a different MAB – Anti-IL, Anti-IgE, Anti-TSLP than requested, will discontinue the other MAB – Anti-IL, Anti-IgE, Anti-TSLP prior to starting the requested agent; **AND**
7. For a non-preferred MAB – Anti-IL, Anti-IgE, Anti-TSLP, **one** of the following:
  - a. Has a history of therapeutic failure of or a contraindication or an intolerance to the preferred MABs – Anti-IL, Anti-IgE, Anti-TSLP approved or medically accepted for the beneficiary's indication
  - b. Has a current history (within the past 90 days) of being prescribed the same non-preferred MAB – Anti-IL, Anti-IgE, Anti-TSLP (does not apply to non-preferred brands when the therapeutically equivalent interchangeable biosimilar or unbranded biologic is preferred or to non-preferred interchangeable biosimilars or unbranded biologics when the therapeutically equivalent interchangeable brand or brand biologic is preferred).

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

See the Preferred Drug List (PDL) for the list of preferred MABs – Anti-IL, Anti-IgE, Anti-TSLP at: <https://papdl.com/preferred-drug-list>;

**AND**

8. For a diagnosis of asthma, **both** of the following:
- a. Has an asthma severity that is consistent with the FDA-approved indication for the prescribed MAB – Anti-IL, Anti-IgE, Anti-TSLP despite maximal therapeutic doses of or contraindication or intolerance to standard asthma controller drugs based on current national treatment guidelines for the diagnosis and management of asthma
  - b. Will use the requested MAB – Anti-IL, Anti-IgE, Anti-TSLP in addition to standard asthma controller drugs as recommended by current national treatment guidelines for the diagnosis and management of asthma;

**AND**

9. For a diagnosis of chronic idiopathic urticaria, **both** of the following:
- a. Has a history of urticaria for a period of at least six weeks
  - b. **One** of the following:
    - i. Requires systemic steroids to control urticarial symptoms
    - ii. Has a history of therapeutic failure of or a contraindication or an intolerance to maximum tolerated doses of an H1 antihistamine taken for at least two weeks;

**AND**

10. For a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), **all** of the following:
- a. Has a diagnosis of EGPA supported by **all** of the following:
    - i. A history of asthma,
    - ii. A history of absolute blood eosinophil count  $\geq 1000$  cells/microL or blood eosinophil level  $>10\%$  of leukocytes,
    - iii. A history of at least **one** of the following:
      - a) Histopathological evidence of **one** of the following:
        - (i) Eosinophilic vasculitis,
        - (ii) Perivascular eosinophilic infiltration,
        - (iii) Eosinophil-rich granulomatous inflammation,

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

- b) Neuropathy, mono or poly (motor deficit or nerve conduction abnormality),
  - c) Pulmonary infiltrates, non-fixed,
  - d) Sino-nasal abnormality,
  - e) Cardiomyopathy,
  - f) Glomerulonephritis,
  - g) Alveolar hemorrhage,
  - h) Palpable purpura,
  - i) Positive test for ANCA,
- b. **One** of the following:
- i. Requires systemic glucocorticoids to maintain remission
  - ii. Has a contraindication or an intolerance to systemic glucocorticoids,
- c. For a beneficiary with severe EGPA as defined by national treatment guidelines, has a history of therapeutic failure of or a contraindication or an intolerance to rituximab or cyclophosphamide;

**AND**

11. For a diagnosis of hypereosinophilic syndrome (HES), **all** of the following:
- a. Has FIP1L1-PDGFR $\alpha$ -negative HES with organ damage or dysfunction,
  - b. Has a blood eosinophil count  $\geq 1000$  cells/microL,
  - c. **One** of the following:
    - i. Requires or has required systemic glucocorticoids to maintain remission
    - ii. Has a contraindication or an intolerance to systemic glucocorticoids;

**AND**

12. For all other diagnoses, has a history of therapeutic failure of or a contraindication or an intolerance to first line therapy(ies) if applicable according to consensus treatment guidelines; **AND**
13. For Xolair (omalizumab) for a diagnosis of asthma, has a diagnosis of allergen-induced asthma (allergic asthma confirmed by either a positive skin test or radioallergosorbent test) to an unavoidable perennial aeroallergen (e.g., pollen, mold, dust mite, etc.); **AND**
14. For Cinqair (reslizumab) for a diagnosis of asthma with an eosinophilic phenotype, has an absolute blood eosinophil count  $\geq 400$  cells/microL; **AND**

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

15. For Nucala (mepolizumab) for a diagnosis of asthma, has asthma with an eosinophilic phenotype with absolute blood eosinophil count  $\geq 150$  cells/microL; **AND**
16. For Fasenra (benralizumab), has asthma with an eosinophilic phenotype with absolute blood eosinophil count  $\geq 150$  cells/microL; **AND**
17. If a prescription for a MAB – Anti-IL, Anti-IgE, Anti-TSLP is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at: <https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/quantity-limits-daily-dose-limits.html>.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

FOR RENEWALS OF PRIOR AUTHORIZATION FOR MABs – ANTI-IL, ANTI-IgE, ANTI-TSLP: The determination of medical necessity of a request for renewal of a prior authorization for a MAB – Anti-IL, Anti-IgE, Anti-TSLP that was previously approved will take into account whether the beneficiary:

1. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
2. Is prescribed a MAB – Anti-IL, Anti-IgE, Anti-TSLP by or in consultation with an appropriate specialist (i.e., pulmonologist, allergist, immunologist, dermatologist, rheumatologist, etc.); **AND**
3. Is not using the requested MAB – Anti-IL, Anti-IgE, Anti-TSLP in combination with another MAB – Anti-IL, Anti-IgE, Anti-TSLP; **AND**
4. For a diagnosis of asthma, **both** of the following:
  - a. Has measurable evidence of improvement in the severity of the asthma condition
  - b. Continues to use the requested MAB – Anti-IL, Anti-IgE, Anti-TSLP in addition to standard asthma controller drugs as recommended by current national treatment guidelines for the diagnosis and management of asthma;

**AND**

5. For a diagnosis of chronic idiopathic urticaria, **both** of the following:
  - a. Experienced improvement of symptoms

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

b. Has a documented rationale for continued use;

**AND**

6. For a diagnosis of HES or EGPA, has **one** of the following:
- a. Measurable evidence of improvement in disease activity
  - b. Reduction in use of systemic glucocorticoids for this indication;

**AND**

7. For a non-preferred MAB – Anti-IL, Anti-IgE, Anti-TSLP with a therapeutically equivalent interchangeable biosimilar or brand or unbranded biologic that is preferred on the PDL, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred therapeutically equivalent interchangeable biosimilar or brand or unbranded biologic that would not be expected to occur with the requested drug.

See the PDL for the list of preferred MABs – Anti-IL, Anti-IgE, Anti-TSLP at:  
<https://papdl.com/preferred-drug-list>;

**AND**

8. If a prescription for a MAB – Anti-IL, Anti-IgE, Anti-TSLP is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at:  
<https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/quantity-limits-daily-dose-limits.html>.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for a MAB – Anti-IL, Anti-IgE, Anti-TSLP. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

D. References

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

1. Cinqair (reslizumab) [package insert]. Frazer, PA: Teva Respiratory, LLC.; Revised January 2019.
2. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med*. 2015;3(5):355-66. doi: 10.1016/S2213-2600(15)00042-9.
3. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. *Chest*. 2016;150(4):789-98.
4. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. *Chest*. 2016;150(4):799-810.
5. Nucala (mepolizumab) [package insert]. Research Triangle Park, NC: GlaxoSmithKline. Revised January 2022.
6. Xolair (omalizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; Revised July 2021.
7. Wenzel S. Treatment of severe asthma in adolescents and adults. In: UpToDate. Updated March 23, 2022. Accessed April 18, 2022.
8. Weller P, Klion AD. Eosinophil biology and causes of eosinophilia. In: UpToDate. Updated August 13, 2020. Accessed April 18, 2022.
9. Khan DA. Chronic urticaria: treatment of refractory symptoms. In: UpToDate. Updated January 21, 2021. Accessed April 18, 2022.
10. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA<sup>2</sup>LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. *Allergy*. 2018;73(7):1393-1414. doi:10.1111/all.13397
11. Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. *J Allergy Clin Immunol Pract*. 2015;3:167-74. doi: 10.1016/j.jaip.2015.01.013.
12. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022. <http://www.ginasthma.org>. Accessed April 18, 2022.
13. U.S. Department of Health, National Institutes of Health, National Heart, Lung, and Blood Institute. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma – Full Report 2007. [https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthgdln\\_1.pdf](https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthgdln_1.pdf). Published October 2007.
14. U.S. Department of Health, National Institutes of Health, National Heart, Lung, and Blood Institute. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Published December 2020.
15. Fasenra (benralizumab) [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals; October 2019.
16. Lantham JG et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. *Medicine*. 1984 Mar;63(2):65-81.
17. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Arthritis Care & Research*. 2021;73(8):1088-1105. doi:10.1002/acr.24634
18. King TE. Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). UpToDate. Updated March 22, 2022. Accessed June 30, 2022.
19. King TE. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis. UpToDate. Updated May 10, 2022. Accessed June 30, 2022.
20. Wechsler ME, Akuthota P, Jayne D, et.al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *NEJM*. 2017;376:1921-32.
21. Supplementary appendix to: Wechsler ME et.al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *NEJM*. 2017;376:1921-32.
22. Roufosse F et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*. 2020 Dec;146(6):1397-1405.
23. Kuang FL, et al. Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome. *The Journal of Allergy and Clinical Immunology: In Practice*. 2018 Sept – Oct; 6(5):1518-1527.
24. Roufosse F. et al. Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis. In: UpToDate. Updated April 6, 2020. Accessed April 18, 2022.
25. Roufosse F. et al. Hypereosinophilic syndromes: Treatment. In: UpToDate. Updated November 4, 2020. Accessed April 18, 2022.